Recent Quotes (30 days)

You have no recent quotes
chg | %

Antibe Therapeutics Inc  

(Public, CVE:ATE)   Watch this stock  
Find more results for ATE
0.0950
Aug 31 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.04 - 0.57
Open     -
Vol / Avg. 0.00/171,199.00
Mkt cap 5.47M
P/E     -
Div/yield     -
EPS -0.08
Shares 49.70M
Beta     -
Inst. own     -
Aug 21, 2015
Q1 2016 Antibe Therapeutics Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -130.56% -171.22%
Return on average equity -204.63% -240.78%
Employees 3 -
CDP Score - -

Address

15 Prince Arthur Ave
TORONTO, ON M5R 1B2
Canada

Website links

Description

Antibe Therapeutics Inc. is a Canada-based company that originates, develops and out-licenses pharmaceuticals that are improved versions of existing drugs. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. The Company's lead compound, ATB-346, combines hydrogen sulfide (H2S) with naproxen, which is an approved, marketed and off patent non-steroidal anti-inflammatory drug (NSAID). The Company has conducted multiple pre-clinical studies, combining the attributes of H2S with naproxen, which have demonstrated that ATB-346, which has therapeutic efficacy that is equal to or greater than that of naproxen while demonstrating an improved side-effect profile versus naproxen and other commonly used NSAID treatments for pain associated with, amongst other conditions, osteoarthritis. The Company investigates other assets in its pipeline, as well as additional development opportunities to which it has access.

Officers and directors

Walter M. Macnee Independent Chairman of the Board
Age: 59
Daniel Legault J.D. President, Chief Executive Officer, Secretary, Director
Age: 56
John L. Wallace Ph.D. Founder, Chief Scientific Officer, Director
Age: 57
Samira Sakhia CPA Chief Financial Officer, Director
Jeremy Grushcow Executive Vice President - Strategic Development
David Vaughan Chief Development Officer
Age: 63
Roderick J. Flower Ph.D. Independent Director
Age: 69
Jonathan Ross Goodman Independent Director
Age: 46